# Is a Higher Semaglutide Dose Worth It? Three Points, Four Times the Symptom What the 7.2 mg semaglutide trial found against the existing dose, what the extra dose cost in side effects, and the one number that does not fit a dose-response story. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it Updated: 2026-09-17 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Is a Higher Semaglutide Dose Worth It? Three Points, Four Times the Symptom A trial put semaglutide 7.2 mg against 2.4 mg in the same protocol. The higher dose bought three more points of weight, and nearly four times the rate of an unfamiliar nerve symptom. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min read weight lost · had GI side effects · 7.2 mg · 18.7% · 70.8% · 2.4 mg · 15.6% · 61.2% · placebo · 3.9% · 42.8% · 1,407 people, randomized against each other in one trial. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A trial randomized 1,407 people to semaglutide at 7.2 mg, at 2.4 mg, or to placebo — so the doses were compared inside one protocol rather than across separate trials. - Weight fell 18.7% at the higher dose against 15.6% at the existing one: an estimated treatment difference of 3.1 percentage points. - Gastrointestinal adverse events rose from 61.2% to 70.8%, and dysesthesia from 6.0% to 22.9%. - Serious adverse events were highest in the 2.4 mg arm (10.9%), not the 7.2 mg arm (6.8%) — which does not fit a simple dose-response story. - Three more points of weight, bought with roughly four times the rate of an unfamiliar symptom. Three more points of weight, bought with roughly four times the rate of an unfamiliar symptom. A trial randomized 1,407 people to semaglutide at 7.2 mg, at 2.4 mg, or to placebo, so the doses were compared inside one protocol rather than across separate trials. Weight fell 18.7% at the higher dose against 15.6% at the existing one. The cost side is not only gastrointestinal. Those events rose from 61.2% to 70.8%, but [dysesthesia](https://thisglp.com/research/does-tirzepatide-cause-skin-sensitivity) — altered sensation — rose from 6.0% to 22.9%. Serious adverse events were highest in the 2.4 mg arm at 10.9%, not the 7.2 mg arm at 6.8%, which does not fit a simple dose-response story. Whether a bigger starting weight changes the trade is a separate question with its own answer. Heavier patients lost more weight and reached the same HbA1c [\[2\]](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it#ref-2), which is [more weight lost and the same glucose result](https://thisglp.com/research/does-starting-weight-change-the-answer). Every seller on this roster has a dose ladder, published or not, and the reason a reader cares is that climbing it costs money. This trial answers the other half of the question: what climbing it buys. It is unusually well designed for that purpose. It put the two doses against each other rather than leaving the comparison to be assembled from separate studies. That is the weakness undermining most such claims, discussed in [tirzepatide against semaglutide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better). ## What was compared Between January 2023 and November 2024, 1,407 adults with obesity were randomized to semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo [\[1\]](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it#ref-1). Nearly three-quarters were female, mean age was 47, mean weight 113 kg and mean BMI 39.9. ## What the higher dose added Mean weight change was −18.7% on 7.2 mg against −15.6% on 2.4 mg, an estimated treatment difference of 3.1 percentage points (95% CI −4.7 to −1.6). Against placebo the difference was 14.8 points. The thresholds show where the extra dose earns its keep. Compared with 2.4 mg, the 7.2 mg arm was 1.8 times likelier to reach a 20% reduction and 2.4 times likelier to reach 25%. At the lower thresholds the two doses were not far apart; the difference is concentrated at the far end. What it cost, in the same table Gastrointestinal adverse events affected 70.8% of the 7.2 mg arm, 61.2% of the 2.4 mg arm and 42.8% of placebo. Dysesthesia — altered or unpleasant sensation, usually tingling or burning — affected 22.9% at the higher dose against 6.0% at the lower and 0.5% on placebo. That last figure is the one worth sitting with. Nearly a quarter of people on the higher dose reported a symptom that barely existed in the other two arms. It is not one most readers will have been warned about. ## The number that does not fit Serious adverse events were reported by 6.8% of the 7.2 mg arm, 10.9% of the 2.4 mg arm and 5.5% of placebo. The highest rate was in the middle dose, which is not what a dose-response relationship looks like. With 201 participants in that arm against 1,004 in the other, the comparison is fragile and the difference may be noise. It is reported here because leaving it out would tidy the result in the drug’s disfavor. A page that only prints the numbers that fit its argument is doing the thing this site exists to catch. ## What a buyer takes from it That the ladder has a top, that the top is worth about three points of weight, and that it costs a substantially higher rate of side effects to stand on. Whether a seller will tell you what the top rung costs in money is a separate matter. It is counted in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder) and listed seller by seller in [published dose ladders](https://thisglp.com/tools/published-dose-ladders). It is also worth knowing that most people never reach a dose like this. Real-world prescribing settles lower and slower than trial protocols. A large share stop before the question arises at all — which is the context for everything above, and the subject of [stopping and weight regain](https://thisglp.com/research/stopping-glp1-and-weight-regain). ## Frequently asked How much more weight does the higher dose produce? 18.7% against 15.6% at 2.4 mg — an estimated treatment difference of 3.1 percentage points, measured inside one trial rather than across separate ones. What does it cost in side effects? Gastrointestinal events rose from 61.2% to 70.8%, and dysesthesia — altered or unpleasant sensation — from 6.0% to 22.9%. Were serious events higher at the higher dose? No, and this is reported rather than omitted: serious adverse events were 6.8% at 7.2 mg against 10.9% at 2.4 mg. With 201 participants in that arm the comparison is fragile. Where does the extra dose earn its keep? At the far end. Against 2.4 mg it was 1.8 times likelier to reach a 20% reduction and 2.4 times likelier to reach 25%, while the lower thresholds were close. ## Sources 1. \[1\] Wharton S, et al. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial The Lancet Diabetes & Endocrinology. [PMID 40961952](https://pubmed.ncbi.nlm.nih.gov/40961952/) 2. \[2\] Almohammed O, Alshaya O, Alduhayshi L, Alshaibani S, et al. (2026). Comparative change in HbA1c and weight outcomes between obese and non-obese adults with type 2 diabetes mellitus treated with SGLT-2 inhibitors or GLP-1 receptor agonists Frontiers in Endocrinology. [PMID 42741141](https://pubmed.ncbi.nlm.nih.gov/42741141/) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)